|
A highly palatable chewable nutritional supplement for the support of
urinary tract health in dogs and cats. Manufactured exclusively for PRN Pharmacal, CranVet
contains ten times higher levels of phenols than other natural products. The patented
process used to formulate the cranberry extract also eliminates unwanted sugars and
oxalic acid resulting in a product that meets the needs of animals with diabetes mellitus.
And CranVet does not interfere with the veterinarian’s choice of antibiotics.
UTI – A Common Problem: Urinary tract infections (UTI) are very common in dogs. An estimated 14% of dogs in the United States develop UTI at least once in their lifetime. Three percent to 9% of all dogs seen at veterinary teaching hospitals have UTI. Less common in cats (1% to 3% incidence), UTI generally occurs in cats older than 10 years. Asymptomatic infections are common in both dogs and cats, especially animals with diabetes mellitus, hyperadrenalcorticism or on glucocorticoids. UTI was diagnosed by in vivo culture in 37% of dogs with diabetes mellitus and 46% with hyperadrenalcorticism in a 2002 study. Eighteen percent of dogs with pruritic disorders receiving long-term treatment with glycocorticoids also had UTI1. UTI is usually caused by bacteria: E. coli accounts for 37% to 67% of isolated uropathogens in dogs2. A study at the University of Georgia shows that 75% of the pathogens were gram negative, including E. coli, Proteus, Klebsiella, Pseudomonas3. Persistent and reoccurring E. coli UTI in dogs is a frustrating clinical problem4.
The majority of P-fimbriae E. coli that cause UTI bind glycosphingolipid receptor sites i.e. α Gal (1 to 4 β Gal disaccharide) on the uro-epithelial cells that are similar to the P blood group antigens on the surface red blood cells5.Furthermore, canine UTI pathogens may pose an infectious threat to humans6. Careful selection of antibiotics remains the treatment of choice for clinical cases. However, since recurrences occur frequently in dogs, complementary use of cranberry extracts should be considered by the clinician.
American Cranberry – It’s a Natural: Vaccinium macrocarpon, the American cranberry, is one of only three species of fruits native to North America. Cranberry is a traditional medicine used by Native Americans for the treatment of bladder and kidney ailments for centuries. Interest in the composition of cranberry has been intensified because of the increased awareness of their possible positive health effects. Berries are a rich source of bioactive compounds, including fiber, vitamins, minerals, various phenolic compounds and citric, malic, quinic and glucoronic organic acids. The chemical structure of the main classes of phenolic compounds in berries is summarized in Figure 1 below 7.
Most of the benefits available from cranberries are derived from the unique structure of natural tannins called proanthocyanidins or PACs. Cranberry PACs contain an unusual A-type linkage different from the more common B-type linkage found in proanthocyanidins from other foods. Two compounds in cranberry juice have been shown to inhibit the adherence of E. coli to uroepithelial cells. Fructose, common to many fruit juices, has been implicated in inhibiting adherence of Type I-fimbriated E. coli; the second, proanthocyanidin, is responsible for inhibiting adherence of the Type P-fimbriated E. coli fimbriae8. Experiments with mice have suggested that a bioactive pro-anthocyanidin metabolite inhibits bacterial adhesion in the urinary tract9. The A-type proanthocyanidins from cranberries elicited in vitro anti-adhesion activity at 60 μg/ml. In contrast, the B-type pro- anthocyanidins from grape juice exhibited only minor activity at 1200 μg/ml while B-type proanthocyanidins found in apple juice, green tea and dark chocolate were not active10. The biological role of bacterial fimbriae is to act as adhesions between the bacteria and receptors on mammalian cells. Cranberry extracts on P-fimbriated E. coli11 inhibit this activity two ways:
1 Torres et al, November, 2005, FEM Journal Volume 252 Issue 2 pp. 183 2 Ling, G.V. et al., 1979, Veterinary Clinician North America (Small Animal Practice), 9, pp. 617-630; Kiristo et al., 1977, Journal of Small Animal Practitioners, 18, pp. 707-712. 3 Finco, D.R., 1980 in Kirk, R.W. (ed) Current Veterinary Therapy VII, Philadelphia, W.B Saunders Co., pp. 1158-1161. 4 2005Drazenovich, N. et al., 2004, Journal of Veterinary Internal Medicine, 18, pp. 301-306; Polzin, D. J., 2006, Compendium Continuing Education Practicing Veterinarians, 28, Supplement, pp. 7-15. 5 Foo, L.Y. et al., 2000, Phytochemistry, 54, pp. 173-181. 6 Johnson, J.R., 2001, Journal of Infectious Disease, 182, pp. 897-906. 7 Puupponen-Pima, R., 2005, Applied Microbial Biotechnology, 67, pp. 8-18. |
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||